

ROLE OF PET/CT IN LIVER MALIGNANCY

Essay

**Submitted For Fulfillment of
Master Degree in
*Radiodiagnosis***

By

Mohamed Salah Metwally
M.B., B.Ch.
Ain Shams University

Supervised By

Prof. Dr. Sameh M. Abd El-Wahab
Professor of Radiodiagnosis
Faculty of Medicine
Ain Shams University

Dr. Mohamed El-Gharib Abou El-Maaty
Lecturer of Radiodiagnosis
Faculty of Medicine
Ain Shams University

**Faculty of Medicine
Ain Shams University**

2010

Acknowledgement

First and foremost, I submit all my gratitude to ALLAH to whom I owe every success in my life.

I would like to express my sincere appreciations and profound gratitude to Prof. Dr. Sameh M. Abd El-Wahab, Professor of Radiodiagnosis, Faculty of Medicine – Ain Shams University, for his help, kind guidance, continuous support & giving me such an honour to work under his supervision.

I would like to express my respect, appreciation, and thanks for Dr. Mohamed El-Gharib Abou El-Maaty, Lecturer of Radiodiagnosis, Faculty of Medicine – Ain Shams University, for his assistance and encouragement.

CONTENTS

	Page
Introduction	1
Aim of the Work	3
Anatomy of the Liver	4
Pathology of Malignant Hepatic Tumors	19
Physical Principles of PET/CT	31
Diagnosis Value of PET/CT in Evaluation of Liver Malignancy	65
Summary	95
References	97
Arabic Summary	--

LIST OF ABBREVIATIONS

^{18}F -FDG	: ^{18}F Fluorine labeled 2 fluoro 2 deoxy glucose
AFP	: Alfa-fetoprotein
CA	: Carbohydrate antigen
CC	: Cholangiocarcinoma
CEA	: Carcinoembryonic antigen
CT	: Computed tomography
GLUT	: Glucose transporters
H^+	: Hydrogen ion
HCC	: Hepatocellular carcinoma
IV	: Intravenous
IVC	: Inferior vena cava
KeV	: Kilo electron volt
MDCT	: Multi detector computed tomography
MeV	: Milli electron volt
MRI	: Magnetic resonant imaging
PEI	: Percutaneous ethanol injection
PET	: Position emission tomography
PET/CT	:Position emission tomography with computed tomography
PMTs	: Photomultiplier tubes
RFA	: Radiofrequency ablation
SMA	: Superior mesenteric artery
SMV	: Superior mesenteric vein
SUV	: Standardized uptake value
TACE	: Transarterial chemoembolization
Z	: Atomic number

LIST OF FIGURES

No.	Title	Page
1	Gross anatomy of liver	6
2	Caudate lobe of the liver	8
3	Drawing illustrates the segmental anatomy of the liver, along with the pattern of hepatic venous drainage, the ramifications of the portal venous system, and the planes of liver transection (dotted line indicates plane of transection in LLS donation, solid line indicates plane of transection in right lobe donation	10
4	Segmental anatomy according to couinoud	10
5	H.Bismuth`s functional classification of the liver. The liver is divided into four sectors by three portal scissurae. Each sector is supplied by portal pedicle. The hepatic viens and portal pedicles are interwind,as are the finger of two hands	11
6	Transverse segmental anatomy of liver LEFT: above the level of left portal vein. RIGHT: at the level of the left portal vein	13
7	Transverse segmental anatomy of liver LEFT: at the level of right portal vein. RIGHT: at the level of splenic vein	14
8	Vascular supply of the liver	16
9	Biliary system anatomy	18
10	Annihilation reaction positrons (B+) released from the nucleus of FDG annihilates with electrons (B+) releasing two coincidence 511-KeV photons which are detected by scintillation crystals	33
11	Schematic presentation showing a ring of multiple specialized crystals detects the "coincidence" 511-KeV photons resulting from positron decay and the subsequent annihilation reaction. Detected of enough coincident events allows reconstruction of an image of the distribution of tracer. This image depicts a trans-axial slice.	34
12	The PET trace is a cyclotron capable of accelerating protons up to final energies of 16.5 MeV and deuterons up to final energies of 8.4MeV. These energies are used to create the commonly used PET radioisotopes Fluride-18, Carbon-11, Nitrogen-13, Oxygen-15, and Cupper-64	37
13	Glucose and Fluorodeoxyglucose structure	38
14	Uptake of FDG. FDG is a glucose analog that is taken up by metabolically active cells by means of facilitated	39

No.	Title	Page
	transport via glucose transporters (GLUT) in the cell membrane. In the cell cytoplasm, FDG undergoes phosphorylation to form FLG-6-phosphate (6p). Which Unlike glucose, Cannot undergo further metabolism and becomes trapped within the cell	
15	A typical PET/CT scanner developed and manufactured by Gemini	42
16	PET/CT scanner shows the PET and CT component	42
17	Whole-body FDG acquisition protocol for the prototype PET/CT. Note, the standard transmission is replaced with a multiple CT scan (tube cooling is needed in case of an extended imaging range) and both IV and oral CT contrast is given to enhance the diagnostic quality of transmission images. Attenuation correction factors are calculated on-line but PET images are reconstructed post-acquisition	49
18	Design of the prototype PET/CT the PET component were mounted on the rear of a common rotating support	50
19	PET/CT image consisting of coronal whole-body CT image (A) , PET image with CT attenuation correction (B), and fused image (C)	51
20	Normal distribution of FDG. Coronal CT (a), PET (b), and PET-CT fusion (c) images demonstrate the physiologic accumulation of FDG in the cerebral-cerebellar cortex at the base of the skull and in the myocardium, liver, kidneys, renal pelvis, bone marrow, and urinary bladder. Note also the minimal uptake in the mediastinum and bilaterally in the lower cervical and psoas muscles	52
21	Physiologic muscle activity. Coronal fused FDG PET-CT image of the back shows bilateral, diffuse, symmetric moderate hypermetabolism in the paraspinal muscles (arrows). Muscular activity due to activity by the patient before or after FDG administration may result in this pattern of radiopharmaceutical uptake.	53
22	Metal ring on left breast of patient (arrow) produces streaking artifacts and high CT numbers (A), resulting in falsely increased radiotracer uptake on PET images with CT attenuation correction (B), whereas PET image without attenuation correction shows only background activity at level of metal ring (C)	60
23	Curvilinear cold artifact (arrow) is commonly seen on dome of diaphragm/liver or at lung base because of	61

No.	Title	Page
	respiration mismatch on PET images with CT attenuation correction	
24	(A) 58-y-old man with colon cancer. Lesion at dome of liver is mislocalized to right lung (arrow) because of respiratory motion. (B) Image without attenuation correction shows that all lesions are confined to liver	62
25	(A) 61 years old patient with lung cancer who ingested barium for an esophagogram 1 d before PET/CT scan. Concentration of contrast medium in colon (arrow) increased because of significant water reabsorption, shown on CT image. (B) High CT numbers of residual barium overcorrect attenuation of PET emission data and mimic increased ^{18}F -FDG uptake on PET image with CT attenuation correction. (C) No increased ^{18}F -FDG uptake is seen on image without attenuation correction	63
26	(A) CT scan shows intravenous contrast medium in right subclavian vein (arrow). (B) Radiotracer uptake is increased in corresponding region of PET image but does not change clinical diagnosis	63
27	54-y-old man with history of metastatic melanoma (arrow). CT image appears truncated at sides (A) and biases PET attenuation-corrected image (B)	64
28	A 33-year-old man undergoing ascending colon cancer resection two years ago. Coronal PET image (A) also showing recurrent lesion (arrow head) at the root of mesentery, ^{18}F -FDG PET (B) and PET/CT fused imaging (D) demonstrating multiple hepatic metastases (arrow), and non-enhanced CT (C) detecting fewer lesions than PET/CT fused imaging (D)	68
29	a Coronal contrast-enhanced CT image with one metastasis of colorectal cancer in the right liver lobe (arrow). b Corresponding coronal PET/CT image with one metastases of colorectal cancer with increased glucose metabolism (arrow). c Corresponding PET image with one metastasis of colorectal cancer with increased glucose metabolism (arrow). d Coronal contrast-enhanced CT image 2 days after RFA covering the same area showing the hypodense ablative area. e Corresponding PET/CT image (red scale) showing a rim-like increased glucose metabolism owing to tissue regeneration after RFA (arrows). f Corresponding PET image (inverted gray scale) showing a rim-like	72

No.	Title	Page
	increased glucose metabolism owing to tissue regeneration after RFA (arrows). g Coronal contrast-enhanced CT image showing 133 days after RFA local tumor recurrence at the right laterocaudal rim of the ablative area (arrow). h Corresponding PET/CT image (red scale) showing 133 days after RFA local tumor recurrence with increased glucose metabolism at the right laterocaudal rim of the ablative area (arrow). i Corresponding PET image showing 133 days after RFA local tumor recurrence with increased glucose metabolism at the right laterocaudal rim of the ablative area (arrow).	
30	PET/CT shows a solitary focal hypermetabolic focus in the right lobe of the liver (arrows) that showed a maximum SUV of 5.7. Corresponding CT of the liver shows a focal hypo echoic mass with indistinct margins	76
31	a Axial contrast-enhanced computed tomography (CT) image 90 days after a radiofrequency ablation (RFA) procedure in the right liver lobe: no evidence of local tumor recurrence. b Corresponding axial positron emission tomography PET/CT image: no evidence of local tumor recurrence. c Corresponding axial PET image : no evidence of local tumor recurrence. d Axial contrast enhanced CT image 230 days after the RFA procedure in the right liver lobe: no evidence of local tumor recurrence (arrow). e Corresponding PET/CT image (red scale) showed local tumor recurrence with increased glucose metabolism at the ventral pole of the ablative area (arrow). f Corresponding PET image (inverted gray scale) showing local tumor recurrence with increased glucose metabolism at the ventral pole of the ablative area (arrow) as well	80
32	38-year man, who had TACE 1 mo before, underwent PET/CT to monitor response to the treatment. Contrast-enhanced arterial-phase axial CT image showed the mass with partial accumulation of iodized oil in the right lobe of the liver (arrows, A, B). A filling defect was detected in the left branch during the portal phases (arrow, C). PET and PET/CT fused images (arrows, D, E and F) revealed residual viable tumor and a highly metabolically active tumor thrombus in the left branch of the portal vein	82
33	Portal phase of contrast-enhanced CT demonstrating the left portal vein tumor thrombus (white arrow)	84

No.	Title	Page
34	A: Integrated PET/CT image showing high FDG uptake by tumor thrombus in the left portal vein (arrow head) and a liver mass with a satellite lesion (arrow); B: Fused PET/CT imaging showing necrosis in the center of the mass (arrow head) with a satellite lesion (arrow).	85
35	MRI T2 imaging showing a thrombus in the left portal vein (white arrow)	86
36	Fused PET/CT imaging showing no hypermetabolism (arrow) in the region of the left portal vein (A) and in the region of previous hepatic resection (B)	87
37	A 68-year-old female complaining of uncomfortable left upper abdomen for one month with increasing of CA19-9 (> 700 m/L) (A), non-enhanced CT (C) detecting a low density lesion in the left lobe of the liver (white arrow), 18F-FDG PET (B) and fused imaging of PET/CT (D) showing necrosis (arrow head) in the center of the mass with a satellite lesion (black arrow). CC was confirmed by liver biopsy.	90

LIST OF TABLES

No.	Title	Page
1	Classification of malignant tumors of the liver	20
2	Risk factor of HCC	25
3	High risk groups for developing hepatocellular carcinoma	25
4	Radionuclides used in PET	35
5	Characteristic of PET and PET/CT modalities in detecting liver malignancies	67
6	Serum markers for HCC	74

ROLE OF PET/CT IN LIVER MALIGNANCY

Abstract:

Dr/ Mohamed Salah Metwally

PET/CT is superior to PET and CT alone and/or magnetic resonance imaging (MRI), in the diagnosis and treatment of various primary or metastatic cancers. It has advantages over other imaging methods; it can differentiate benign from malignant lesions, staging and restaging tumors, detect functional changes before there is any change in clinical or radiological size of a mass, better in identify cancer that has spread, making up treatment plane and monitoring tumor response, detect tumor recurrence early and distinguish viable metabolically active tissue from scars.

¹⁸F-FDG PET has advantages over conventional imaging techniques in designing and evaluating managements of hepatic malignancies. PET/CT is more and more widely applied in clinical practice. It is more sensitive and specific than PET, with a lower false positive and false negative rate.

The ability of PET/CT with ¹⁸F-FDG to enhance the patients suffering from hepatic metastases, HCC and CC by more accurate diagnosis, staging restaging and further evaluation of their biologic characteristics.

Whole body positron emission tomography with (18) F-fluoro-deoxy-glucose (FDG) in combination with CT scanning (PET/CT) represents one of the most sensitive imaging modalities for the detection of hepatic metastases and extra hepatic tumor manifestations. For the staging and follow up of colorectal cancer, FDG-PET/CT represents a standard imaging modality.

¹⁸F-FDG PET/CT is useful in the evaluation of HCC metastasis, although its role in the diagnosis of primary HCC is more limited. Dual tracer PET/CT had an incremental value and complementary advantage when compared with signal tracer imaging in the evaluation of HCC metastasis and lymph node.

The ability of FDG-PET quantitatively to estimate metabolic rates makes it an important tool for monitoring. With increasingly broad indications for FDG-PET imaging, it is expected that FDG-PET (and PET/CT) of the liver will play a growing and increasingly important role in detecting and monitoring treatment of tumors involving the liver.

Conventional imaging modalities have limitations in discriminating portal vein tumor thrombus.

¹⁸F-FDG PET/CT was more sensitive than conventional CT and MRI in detecting suspected vein tumor thrombus in patients with HCC. Tumor thrombus differentiates it self from blood thrombus by its intense uptake of ¹⁸F-FDG as a result of high metabolic neoplastic activity.

PET and PET/CT is very important in patients with unexplained high levels of tumor markers.

Ultimately PET/CT provides a new horizon in diagnosis and follow up of treatment of various tumour that needs more researches.

INTRODUCTION

Cancer is one of the leading causes of morbidity and mortality even in the developed countries. Complex clinical decisions for treatment of tumors are largely guided by imaging findings. Most radiological procedures map the anatomy and morphology of tumors with little or no information about their metabolism (*Kapper et al., 2004*).

Because of the importance of the liver as it is one of the most common locales for spread of the malignant diseases. It is the abdominal organ of greatest interest for the use of imaging studies (*Semelka et al., 2005*).

Modern cross sectional structural imaging techniques like ultrasonography, computed tomography (CT) and magnetic resonance imaging (MRI) provide high resolution images that aid in accurate detection, delineation and anatomic localization of liver malignancies. However, characterization of lesions into benign and malignant etiologies is often not possible from structural imaging techniques alone. Although functional imaging techniques like positron emission tomography (PET) with radio labeled ^{18}F labeled 2-fluoro-2-deoxy-glucose (^{18}F -FDG) often provide critical information pertaining to a benign or malignant etiology (*Wahl, 2004*).

The CT portion of PET/CT provides valuable anatomic and pathologic information to functional information provided

by PET and help improve the overall accuracy of the combined study (*Kamel et al., 2004*).

Positron emission tomography (PET) is a functional imaging modality that has been documented to be useful in patient care. Oncologic PET imaging is used for a wide variety of neoplasms. Mainly for staging and follow up, differentiation of equivocal morphologic findings, therapy stratification and monitoring (*Rosenbaum et al., 2006*).

Because PET imaging is based on the physiologically mediated distribution of the administrated tracer but not on anatomic information, the addition of computed tomography (CT) to (PET) may improve the interpretation of PET. Combined PET and CT offers several potential advantages over PET alone that may influence the clinical routine (*Rosenbaum et al., 2006*).

Advances in imaging technology have improved our ability to detect, characterize and stage metastatic liver disease. PET/CT therefore possibly proved superior to CT alone when assessing liver cancer (*Veit et al., 2006*).

AIM OF THE WORK

The aim of this work is to evaluate the role of PET/CT in liver imaging regarding the advantages over conventional techniques in designing and evaluating managements of hepatic malignancies.
